Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Update on fenoldopam regulatory submission

May 24, 1996

Progress on endothelin antagonists at Texas Biotechnology

May 24, 1996

More angiotensin II antagonists from Japanese companies

May 24, 1996

ADIR claims compounds for venous insufficiency

May 24, 1996

ADIR claims imidazoline I1 receptor ligands for hypertension

May 24, 1996

Baxter will develop graft system developed by Australian investigators

May 24, 1996

Lilly reports agents for septic shock

May 17, 1996

Fujisawa isolates cGMP PDE inhibitor from Pseudomonas

May 17, 1996

Merck & Co. claims class III antiarrhythmics

May 17, 1996

FK-409 claimed as portal hypertension Rx

May 17, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...